Amiodarone, an iodinated benzofuranic derivative, was introduced in the 1960s as an antianginal agent for its coronary vasodilator property. Later it was broadly applied as an antiarrhythmic agent. Amiodarone affects thyroid function as a result of both iodine release and intrinsic drug properties. The incidence of Amiodarone induced thyrotoxicosis (AIT) is 5-10% in reports of most studies. There are two types of AIT, designated as type 1 and type 2. Type 1 AIT occurs in abnormal thyroid glands (nodular goiter, latent Graves’ disease) and type 2 AIT in apparently normal thyroid glands. But mixed or indefinite form, the combination of these 2 forms does exist. This form maybe caused by both pathogenic mechanisms. Here we reported a patient with type 2 AIT who presented not only with common manifestations of type 1AIT but also gained euthyroid state with steroid therapy.